Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genasense + Fludarabine + Rituximab in CLL
NCT00078234Phase 2Completed
- Sponsor
- Genta Incorporated
- Start
- Nov 2003
- Primary completion
- Sep 2008
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oblimersen in chronic lymphocytic leukemia (CLL), sponsored by Genta Incorporated. Primary endpoints: Safety and Complete Response Rate. Started Nov 2003; status: completed.
02
Drugs
oblimersen
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00078234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078234.